Exhibit 99.5
Proactive Email to National PAO Leaders
Hi [name]
I’m reaching out to share an update from our team at bluebird: the company has entered into an agreement to be acquired and taken private by a team of highly experienced biotechnology investors and executives. This is significant and positive step forward in bluebird’s mission to bring potentially transformative therapies to patients impacted by severe genetic diseases.
This new chapter is expected to bring financial stability and additional investments to expand access and improve the gene therapy experience for patients and families. While this will mean changes for bluebird, including a new leadership team expected to be headed by David Meek as CEO, our commitment to patient access and partnering with the [CALD/beta-thalassemia/sickle cell disease community] remains as strong as ever and all activities related to treatment manufacturing and patient care will continue as usual.
David has offered to join an upcoming monthly call to discuss their vision for expanding access to gene therapies and their commitment to the [CALD/beta-thalassemia/sickle cell disease community] and answer questions you may have—please let me know if you would like me to coordinate that discussion. Feel free to call me directly if you have any questions or concerns.
Thank you,
Tonya
ADDITIONAL INFORMATION AND WHERE TO FIND IT
The tender offer for the outstanding shares of bluebird bio referenced in this communication has not yet commenced. This communication is not an offer to buy nor a solicitation of an offer to sell any securities of bluebird bio. The solicitation and the offer to buy shares of bluebird bio common stock will only be made pursuant to a Tender Offer Statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that Beacon Parent Holdings, L.P. (“Parent”) and Beacon Merger Sub, Inc. (“Merger Sub”) intend to file with the Securities and Exchange Commission. In addition, bluebird bio will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. Once filed, investors will be able to obtain a free copy of these materials and other documents filed by Parent, Merger Sub and bluebird bio with the SEC at the website maintained by the SEC at www.sec.gov. Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by bluebird bio under the “investors & media” section of bluebird bio’s website at www.bluebirdbio.com.
INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE, INCLUDING THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 OF BLUEBIRD BIO AND ANY AMENDMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE TENDER OFFER AND THE MERGER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES INTO THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.